Publications
MAP present at major conferences such as ISPOR as well as publishing our own view points on particularly hot topics. See our publications, presentations and papers here with many more presentations available within our website.
Publication Categories
- All Publications
- Consultation responses
- ISPOR posters
- Other posters
- Policy reports
- Policy summaries
- Research
- MAP submission to the NHS England consultation on the draft Commercial Framework for Medicines
- ISPOR 2019 – Copenhagen: Trends in the use of PAS and CAA in HTAs carried out by NICE
- ISPOR 2019 – Copenhagen: Impact of conditional marketing authorisation and accelerated assessment on HTA outcomes
- ISPOR 2019 – Copenhagen: An analysis of restricted recommendations by NICE
- Exploring the Burden of X-Linked Hypophosphataemia: An Opportunistic Qualitative Study of Patient Statements Generated During a Technology Appraisal
- Infographic of Access to Orphan Medicines: A Case for Change
- MAP submission to APPG consultation on NICE methods
- MAP submission to the Health and Social Care Committee consultation on the availability of Orkambi on the NHS
- MAP submission to NICE consultation on principles that guide NICE guidance and standards
- Access to Orphan Medicines: A Case for Change
- ISPOR 2018 – Barcelona: Do Early Access schemes in the UK increase the likelihood of reimbursement and patient access?
- ISPOR 2018 – Barcelona: A review of the NICE medical technologies evaluation programme for assessing medical devices and diagnostics in the UK
- ISPOR 2018 – Barcelona: The impact of international reference pricing in Europe
- ISPOR 2018 – Barcelona: An examination of HTA outcomes where a patient access scheme or managed access agreement was used
- ISPOR 2018 – Barcelona: Does reimbursement through the cancer drugs fund impact patient access in the UK?
- ISPOR 2018 – Barcelona: Is patient access affected by the use of carer disutility in NICE highly specialised technology submissions?
- ISPOR 2018 – Barcelona: Bridging the gap: Ensuring fair assessment of orphan treatments by health technology assessments in England
- MAP BioPharma response to consultation on proposed changes to the statutory scheme to control the cost of branded health service medicines
- MAP BioPharma response to consultation on charging for technology appraisal and highly speciaised technology recommendations and miscellaneous amendments to NICE legislation
- MAP submission to NHS England’s consultation on the conditions for which over the counter items should not routinely be prescribed in primary care
- MAP submission to the second phase of the NICE consultation on increasing capacity within Technology Appraisals
- MAP submission to NICE consultation on increasing capacity within Technology Appraisals
- ISPOR 2017 – Glasgow: Sustainability and Transformation Partnerships (STPs)
- ISPOR 2017 – Glasgow: Patient Access Schemes (PAS)
- ISPOR 2017 – Glasgow: Orphan Products in England
- ISPOR 2017 – Glasgow: MedTech Innovation Briefings (MIBs)
- ISPOR 2017 – Glasgow: Managed Access Agreements (MAAs)
- ISPOR 2017 – Glasgow: HTA Launch Sequence – UK & I
- ISPOR 2017 – Glasgow: Generic Cancer Medicines
- ISPOR 2017 – Glasgow: Brexit
- ISPOR 2017 – Glasgow: ATMP Pricing
- ISPOR 2017 – Glasgow: Uptake of Ultra Rare Diseases: Ataluren Case Study
- MAP submission to Health and Social Care Committee inquiry into Brexit – medicines, medical devices and substances of human origin
- The Life Sciences Industrial Strategy
- MAP submission to the House of Lords Science and Technology Committee’s inquiry into the future of UK Life Sciences
- Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis
- Changes to access to medicines in Scotland
- The consequences of Brexit in Spain – a life sciences perspective
- ISPOR 2016 – Vienna: Predicting Orphan Designation and Marketing Authorisation Based on a Review of the European Medicines Agency Orphan Disease Register
- ISPOR 2016 – Vienna: Review of Health Technology Assessment Requirements for Rare Diseases Across European Countries
- ISPOR 2016 – Vienna: Review of the Recommendation made by NICE and SMC Relating to Treatments for Rare Diseases
- ISPOR 2016 – Vienna: Review of National Policies for Rare Diseases Across EU Countries
- ISPOR 2016 – Vienna: A Systematic Literature Review of Health Economics Evaluations of Treatments for Rare Diseases
- Brexit and the Life Sciences Sector
- The Patient Handbook: a Practical Guide for Research and Drug Development by Anthony Hall et al
- Enforceability of NICE Guidance and Guidelines
- EU and US Pricing and Reimbursement for Innovative Medicines
- ISPOR 2015 – Milan: The Cancer Drugs Fund
- ISPOR 2015 – Milan: The UK Pharmaceutical Price Regulation Scheme (PPRS)
- ISPOR 2015 – Milan: Vaccines
- ISPOR 2015 – Milan: CE Marking
- American Thoracic Society 2015
- ISPOR 2015 – Philadelphia: HTA trends in the UK and Germany
- ISPOR 2015 – Philadelphia: G-BA trend analysis in Germany
- ISPOR 2015 – Philadelphia: Cost-minimisation is an option in HTA submissions
- ISPOR 2015 – Philadelphia: SMC decisions – Trends
- ISPOR 2015 – Philadelphia: SMC changes and access to Orphans
- ISPOR 2015 – Philadelphia: NICE technology appraisals – Trends
- ISPOR 2015 – Philadelphia: EU flat pricing and transparency rules
- ISPOR 2015 – Philadelphia: Implementation of NICE Guidelines
- ISPOR 2015 – Philadelphia: SME preparedness for market entry
- ISPOR 2015 – Philadelphia: NICE topic selection
- Estimated cost and payment by results tariff reimbursement for idiopathic pulmonary fibrosis services across 14 specialist providers in England
- Connectivity in the Life Sciences and Healthcare Sectors: Fast-tracking BioPharma innovation to patients in Europe
- The UK Pharmaceutical Price Regulation Scheme (PPRS) and the Statutory Regulations
Sorry, no results for this search